Evoke Wealth’s Sage Therapeutics SAGE Stock Holding History

Evoke Wealth’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-33	Closed	-$948	–	1174
2020 Q1	$948	Buy	+33	New	+$1.91K	﹤0.01%	936
2019 Q4	–	Sell	-11	Closed	-$1.54K	–	1432
2019 Q3	$1.54K	Buy	+11	New	+$1.84K	﹤0.01%	1253

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Evoke Wealth's SAGE Position: Q2 2020 in Review

Evoke Wealth sold out of Sage Therapeutics (SAGE) in Q2 2020, closing a stake of 33 shares — an estimated $948 sold.

Evoke Wealth first reported a position in SAGE in Q3 2019 and held it in 2 quarters. The position peaked at $1.54K in Q3 2019. 217 funds tracked by Wall St. Rank hold SAGE as of Q2 2020.

Evoke Wealth reported no remaining Sage Therapeutics position as of Q2 2020 after selling out during the quarter.
Evoke Wealth sold 33 Sage Therapeutics shares in Q2 2020, an estimated $948.
Evoke Wealth first reported a position in Sage Therapeutics in Q3 2019 and held it in 2 quarters.
Evoke Wealth's Sage Therapeutics position peaked at $1.54K in Q3 2019.
217 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2020.

Based on Evoke Wealth's 13F filing for Q2 2020, filed 10 Aug 2020.